Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.54 |
| ▸ | DRD3 | P35462 | 11/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | PTAFR | P25105 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5557294 | 0.91 | NAMPT (0.51) | DRD2DRD3ALOX5HDAC4HDAC1 | |
| SCHEMBL5557428 | 0.90 | DRD2 (0.48) | DRD2DRD3ALOX5PTAFRALDH1A1 | |
| SCHEMBL10667576 | 0.87 | ALOX5 (0.66) | DRD2DRD3ALOX5HDAC4HDAC1 | |
| SCHEMBL81910 | 0.85 | PTAFR (0.50) | PTAFRALDH1A1 | |
| SCHEMBL3458409 | 0.84 | ALDH1A1 (0.63) | DRD2DRD3PTAFRALDH1A1 | |
| SCHEMBL81394 | 0.84 | PTAFR (0.49) | PTAFRALDH1A1 | |
| SCHEMBL82430 | 0.84 | PTAFR (0.49) | PTAFRALDH1A1 | |
| SCHEMBL83930 | 0.84 | LMNA (0.49) | PTAFRALDH1A1 | |
| SCHEMBL7672874 | 0.84 | CHRNA7 (0.57) | DRD2DRD3PTAFRALDH1A1 | |
| SCHEMBL3079286 | 0.83 | PTAFR (0.48) | PTAFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4599062-B2 | — | — | 2010-12-15 | — | — | JP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | claimed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | claimed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | claimed |
| JP-2005528361-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | claimed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | claimed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | claimed |
| EP-1487444-B9 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2010-07-21 | — | — | EP | disclosed |
| EP-1487444-B1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | ASTELLAS DEUTSCHLAND GMBH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | ASTELLAS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1487444-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | Fujisawa Deutschland GmbH (DE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080054-A1 | USE OF PYRIDYL AMIDES AS INHIBITORS OF ANGIOGENESIS | FUJISAWA DEUTSCHLAND GMBH (DE) | 2003-10-02 | — | — | WO | disclosed |
| EP-1348434-A1 | Use of pyridyl amides as inhibitors of angiogenesis | Fujisawa Deutschland GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-4778796-A | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0210782-A2 | Pyridine compounds, process for the preparation thereof and pharmaceutical composition containing the same | Dainippon Pharmaceutical Co., Ltd. (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052419-A1 | Use of pyridly amides as inhibitors of angiogenesis | FLT1, VEGFA, FLT4 | DRD2 4246/4885DRD3 4622/4885ALOX5 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.